FY2028 EPS Estimate for Kodiak Sciences Boosted by Analyst

Key Points

• HC Wainwright raised Kodiak Sciences’ FY2028 EPS estimate to a loss of $0.97 per share from a previous forecasted loss of $1.78, while maintaining a “Buy” rating and $126 price target. The firm projects FY2029 EPS of $2.19.
• Kodiak’s latest quarterly results missed expectations, with a $1.05-per-share loss versus the consensus estimate of $0.96. Despite mixed analyst views, the stock has an overall “Moderate Buy” consensus rating and an average price target of $104.71.
• Institutional investors own 89.06% of the company, while insiders hold 44.40%; insiders purchased nearly 1.94 million shares worth approximately $157 million during the last quarter.

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Equities researchers at HC Wainwright boosted their FY2028 EPS estimates for shares of Kodiak Sciences in a report released on Monday, October 12th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.97) for the year, up from their previous estimate of ($1.78). HC Wainwright has a "Buy" rating and a $126.00 price target on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.97) per share. HC Wainwright also issued estimates for Kodiak Sciences' FY2029 earnings at $2.19 EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.09).

Other equities research analysts also recently issued research reports about the company. Weiss Ratings downgraded Kodiak Sciences from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, October 6th. UBS Group increased their target price on Kodiak Sciences from $80.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday, September 28th. JPMorgan Chase & Co. raised their target price on Kodiak Sciences from $56.00 to $66.00 and gave the company an "overweight" rating in a report on Monday, August 3rd. The Goldman Sachs Group restated a "neutral" rating and set a $103.00 target price on shares of Kodiak Sciences in a report on Wednesday, September 30th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $112.00 target price on shares of Kodiak Sciences in a research report on Monday, September 28th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $104.71.

Kodiak Sciences Stock Down 7.7%

KOD opened at $91.63 on Wednesday. Kodiak Sciences has a 52 week low of $10.94 and a 52 week high of $104.00. The business has a fifty day simple moving average of $50.99 and a 200-day simple moving average of $43.35. The firm has a market cap of $5.76 billion, a P/E ratio of -21.87 and a beta of 2.03.

Hedge Funds Weigh In On Kodiak Sciences

Institutional investors have recently modified their holdings of the business. V Square Quantitative Management LLC purchased a new stake in Kodiak Sciences during the 1st quarter worth about $26,000. Westfuller Advisors LLC purchased a new position in shares of Kodiak Sciences in the 1st quarter valued at about $26,000. KBC Group NV purchased a new position in shares of Kodiak Sciences in the 1st quarter valued at about $39,000. EverSource Wealth Advisors LLC grew its position in shares of Kodiak Sciences by 94.5% during the first quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company's stock worth $73,000 after buying an additional 936 shares in the last quarter. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Kodiak Sciences during the second quarter worth about $228,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Insider Transactions at Kodiak Sciences

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker bought 33,726 shares of Kodiak Sciences stock in a transaction on Tuesday, September 29th. The shares were bought at an average cost of $85.05 per share, for a total transaction of $2,868,396.30. Following the acquisition, the director directly owned 20,191,214 shares in the company, valued at $1,717,262,750.70. This represents a 0.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have purchased 1,941,755 shares of company stock worth $156,986,026. 44.40% of the stock is owned by corporate insiders.

About Kodiak Sciences

Kodiak Sciences Inc NASDAQ: KOD is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company's research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye.

Kodiak's lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.